Britain Approves Moderna's COVID-19 Vaccine For Kids Aged 6-11 Years

• Britain's medicines regulator approved the use of Moderna Inc's (NASDAQ:MRNA) COVID-19 vaccine in children between six and 11 years.
• The Medicines and Healthcare products Regulatory Agency (MHRA) said the approval was granted after Moderna's vaccine, known as Spikevax, met the required safety, quality, and effectiveness standards.
• Read Next: Why Did Moderna Recall Thousands Of COVID-19 Vaccine Doses In Europe?
• This approval considers the extension to use in children aged 6 to 11 years already approved by the European Medicines Agency in March. The original Great Britain license for Spikevax in adults was approved by relying on the EU decision.
• The approval comes hours after the regulator approved Valneva SE's (NASDAQ:VALN) COVID-19 vaccine for adults up to 50 years.
• Price Action: MRNA shares are down 2.24% at $165.86 during the market session on the last check Thursday.
• Photo by mufidpwt via Pixaby